B7-H3-directed antibody-drug conjugate reduced the risk of death by 54% compared with topotecan and improved progression-free survival and response rates SEOUL, South Korea, Sept. 13, 2026 /PRNewswire/ -- Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug...
Hence then, the article about phase iii artemis 008 trial shows risvutatug rezetecan significantly improves overall survival in relapsed small cell lung cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancer )
Also on site :
- ‘I’m a Rheumatologist—These Are the Symptoms I Ask About Before Suspecting Autoimmune Disease’
- Driscoll touts Ukraine's military innovation in first public appearance since resigning as Army Secretary
- ‘Animal Hospital’ Leads Roblox Innovation Awards 2026 Winners as Roblox Unveils 20th Anniversary Event